Laekna HK$791 million IPO
We advised Laekna on its IPO and HKEX listing
Davis Polk advised Laekna, Inc. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Regulation S. The net proceeds from the offering amounted to approximately HK$791 million.
Founded in 2016, Laekna, Inc. is a science-driven, clinical-stage biotechnology company. It has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials and has initiated one clinical trial and another five clinical trials for its core products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers.
The Davis Polk corporate team included partners Xuelin (Steve) Wang, Yang Chu and Jason Xu, associates Jenny Ho and Michelle Chow and registered foreign lawyers Wentian Xie and Haiyang Zhao. Members of the Davis Polk team are based in the Hong Kong and Beijing offices.
Related Posts
Antalpha Ventures, Web3Labs, and Goldford-HB Launch Computational Power Fund for AI and Web3 Projects
Antalpha Ventures, a global investment firm at the forefront of cutting-edge technology, has partnered with renowned Asian Web3 incubator Web3Labs and venture capital firm Goldford-HB to launch a new computational power fund. This fund aims to support early to mid-stage AI and Web3 projects worldwide by providing the necessary computational resources. Fund Back
Connecting the Future: Web3Labs, IoTeX, and Goldford-HB Ventures Jointly Launch Global Recruitment for DePIN Project
Recently, Asia’s well-known Web3 accelerator Web3Labs officially announced that it will join forces with DePIN infrastructure leader IoTeX and venture capital firm Goldford-HB Ventures to launch a new round of global recruitment for DePIN projects. Committed to finding and cultivating project teams with innovative spirit and strong potential for joint investm
NGS test completed in one day, lung and colon cancer test kits receive FDA approval
NGS (next generation sequencing technology), also known as high-throughput sequencing technology. It is commonly used for genetic disease screening, prenatal testing or diagnosis, oncology clinical diagnosis, pharmacogenomic testing, cancer chemotherapy and treatment, and single gene disease screening or diagnosis. It is capable of sequencing hundreds of thousa
Pillar Biosciences Closes $29.7 Million in Series C Financing
May 12, 2020NGS clinical cancer diagnostics company Pillar Biosciences held a Series C financing signing ceremony at its headquarters in Boston, USA, officially announcing the completion of a $29.7 million Series C financing round led by ORI Healthcare Fund, which raised Series A funding. The financing will accelerate the expansion of Pillar’s R&D pro